A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000510640

Enrollment

Registered

2005-09-26

Start date

2004-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Addition of gefitinib to chemoradiation; 2-4 weeks of gefitinib followed by 6 weeks chemoradiation + gefitinib

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Resected SCC oral cavity, oropharynx, hypopharynx or larynx; risk factors for recurrence; no macroscopic residual disease, no prior radiotehrapy for head and neck cancer, no prior chemotherapy.

Exclusion criteria

No exclusion criteria

Outcome results